Mark L. Pacala - 21 Sep 2022 Form 3 Insider Report for Oncology Institute, Inc. (TOI)

Role
Director
Signature
/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mark L. Pacala
Issuer symbol
TOI
Transactions as of
21 Sep 2022
Net transactions value
$0
Form type
3
Filing time
23 Sep 2022, 16:12:34 UTC
Next filing
21 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TOI Common stock 20,248 21 Sep 2022 Direct F1
holding TOI Common stock 30,372 21 Sep 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TOI Stock Option (right to buy) 21 Sep 2022 Common stock 147,845 $0.8500 Direct F3
holding TOI Stock Option (right to buy) 21 Sep 2022 Common stock 93,734 $0.8500 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted earn-out shares subject to forfeiture and unvested until such time that the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the business combination of the Issuer, pursuant to that certain Agreement and Plan of Merger dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC, and TOI Parent, Inc., that closed on November 12, 2021 (the "Business Combination").
F2 Represents restricted earn-out shares subject to forfeiture and unvested until such time that the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination.
F3 These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of April 1 2019 (the "Original Grant Date"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date.
F4 These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney